

Alanine aminotransferase (ALT/GPT) UV-Kinetic (4+1)

IVD

REF.	Pack size
179 02 020	(2 x 20 ml) 40 tests
179 01 050	(1 x 50 ml) 50 tests
179 10 010	(10 x 10 ml) 100 tests
179 04 050	(4 x 50 ml) 200 tests

Intended Use

ALT reagent is intended for the in-vitro quantitative and diagnostic determination of ALT in human serum on both automated and manual systems.

Introduction

The enzyme alanine aminotransferase ALT is widely distributed with high concentrations in the liver and to a lesser extent in kidneys, heart, skeletal muscles, pancreas and lungs. Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, liver carcinoma and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. Although both serum aspartate aminotransferase (AST) and ALT become elevated whenever disease processes affect liver cell integrity, ALT is the more liver specific enzyme. Moreover, elevations of ALT activity persist longer than elevations of AST activity.

Method

Kinetic method according to the International Federation of Clinical Chemistry (IFCC).


Principle

The series of the reaction involved in the assay system is as follows:


- The amino group is enzymatically transferred by ALT present in the sample from alanine to the carbon atom of 2-oxoglutarate yielding pyruvate and L-glutamate.



- Pyruvate is reduced to lactate by LDH present in the reagent with the simultaneous oxidation of NADH to nicotinamide adenine dinucleotide (NAD). The reaction is monitored by measuring the rate of decrease in absorbance at 340 nm due to the oxidation of NADH.



- Endogenous sample pyruvate is rapidly and completely reduced by LDH during the initial incubation period so that it does not interfere with the assay.



Reagents

Reagent 1 (Buffer)

Tris buffer(pH 7.4)	100 mmol/L
L- Alanine	800 mmol/L
LDH	≥ 2000 U/L
Sodium Azide	8 mmol/L

Reagent 2 (Coenzyme)

NADH	≥ 0.18 mmol/L
2 – Oxoglutarate	18 mmol/L
Sodium Azide	8 mmol/L

Reagent preparation, storage and stability

Prepare working solution as following:

Prepare working solution by adding 4 volumes from R1 and 1 volume of R2, e.g. 400 µl R1 + 100 µl R2.

Working solution is stable for 4 weeks at 2 – 8 °C or 2 days at 15 - 25 °C.

All reagents are stable until expiration date stated on label when stored refrigerated at 2 - 8 °C. Once opened, the reagent is stable for 2 months at the specified temperature.

Deterioration

Do not use liquizyme ALT reagent if it is turbid or if the absorbance of the working reagent is less than 1.0 at 340 nm. Failure to recover control values within the assigned range may be an indication of reagent deterioration.

Precautions and Warnings

Do not ingest or inhale. In case of contact with eyes or skin; rinse immediately with plenty of soap and water. In case of severe injuries; seek medical advice immediately. Both reagents (R1) and (R2) contain sodium azide which may react with copper or lead plumbing.

Specimen collection and preservation

Use non-hemolyzed serum or plasma. Heparin and EDTA are the only acceptable anticoagulants; avoid other anticoagulants. The biological half-life of ALT in serum is 47 hours.

Stability: 3 days at 15 - 25 °C or 7 days at either 4- 8 °C or at -20 °C

Procedure

Wavelength	340 nm
Optical path	1 cm
Assay type	Kinetic
Direction	decrease
Sample : Reagent Ratio	1 : 10
Temperature	37 °C or 30 °C
Equilibration time	60 seconds
Read time	1 to 3 minutes
Zero adjustment	Against air
Reagent Blank Limits	Low 1.00 AU High 2.5 AU

Working solution 1.0 ml

Specimen 100 µl

Mix, read initial absorbance after 60 seconds and start timer simultaneously. Read again after 1, 2 and 3 minutes. Determine the mean absorbance change per minute (ΔA/min).

Calculation

To calculate the ALT/GPT activity use the following formula

$$U/L = 1746 \times \Delta A \text{ 340 nm /min}$$

Quality control

Normal and abnormal control serum of known concentration should be analyzed with each run.

Sensitivity

When run as recommended, the minimum detection limit of this assay is 5.0 U/L.

Linearity

The reaction is linear up to ALT concentration of 400 U/L; specimens showing higher concentration should be diluted 1+5 with physiological saline and repeat the assay (result×6).

Interference

Hemolysis

Erythrocyte contamination elevates results, since ALT activities in erythrocytes are 3 to 5 times higher than those in normal sera.

Icterus

No significant interference.

Lipemia

Lipemic specimens may cause high absorbance flagging. Diluted sample is recommended.

Anticoagulants

Citrate and fluoride inhibit the enzyme activity.

Drugs

Calcium dobesilate and doxycycline HCL cause artificially low ALT values at the tested drug level.

Expected values

37 °C	Females	up to 31 U/L	(up to 0.52 µKat/L)
	males	up to 41 U/L	(up to 0.68 µKat/L)
30 °C	Females	up to 22 U/L	(up to 0.37 µKat/L)
	males	up to 29 U/L	(up to 0.48 µKat/L)

Performance characteristics

A comparison between ALT (4+1) reagent and a commercial reagent of the same methodology was performed on 20 human sera. A correlation of 0.983 was obtained.

Precision

Within run (Repeatability)

	Level 1	Level 2
n	20	20
Mean (U/L)	24.6	105.9
SD	0.93	0.94
CV%	3.78	0.89

Run to run (Reproducibility)

	Level 1	Level 2
n	20	20
Mean (U/L)	25.2	106
SD	1.1	1.05
CV%	3.9	0.95

Waste Disposal

This product is made to be used in professional laboratories. Please consult local regulations for a correct waste disposal. **S56:** dispose of this material and its container at hazardous or special waste collection point.

S57: use appropriate container to avoid environmental contamination.

S61: avoid release in environment. refer to special instructions/safety data sheets.

References

1. Breuer J, report on the symposium "drug effects in clinical chemistry methods". Eur J Clin Chem Clin Biochem. 1996;34:385-386.
2. ECCLS. Determination of the catalytic activity concentration in serum on L- alanine aminotransferase (EC 2.6.1.2,ALAT) Clin chem. 1989;20:204-211.
3. IFCC expert panel on enzymes part 3. J Clin Chem Clin Biochem 1986;24:481-95 .
4. Henry RJ, et al. Am J clin Path 1960 :34:381
5. Sherwin JE. Liver function. In:kaplan LA, PESCE AJ, eds. Clinical chemistry, theory, analysis, and correlation. St louis:mosby; 1984:420-438.
6. Young DS. Effects of drugs on clinical laboratory tests. Third edition. 1990 :3:6-12.

SYMBOLS IN PRODUCT LABELLING



For in-vitro diagnostic use



Batch Code/Lot number



Catalogue Number



Consult instructions for use



Temperature Limitation




Use by/Expiration Date



CAUTION. Consult instructions for use



Manufactured by

 Spectrum For Diagnostics Industries - Free Zone
Ismailia Free Zone Industrial Area, Block 5 .
Cairo- Port said Avenue.
Ismailia, Egypt
Tel: +2 064 3488 013 - +2 064 3488 014 Fax: +2 064 3488 015
www.sdi-fz.com



MDSS GmbH
Schiffgraben 41
30175 Hannover, Germany



IFUF179

Rev.(2), 13/6/2020